# HUGO BIOTECH

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hugo-biotech

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.hugobiotech.com
- Total disclosed funding: $110M
- Latest round: Series C (Jan 21, 2022)
- Investors on record: 6

## About

Based in Beijing, China and established in 2017, HUGO BIOTECH is a health care company that focuses on microbial sequencing and microbial genome big data analysis. The company has gene sequencing laboratories in Guangzhou, Shanghai, Hefei and Chengdu. It has a microbial research and development team, a clinical experiment team and a bioinformatics analysis team. The company has completed 5 rounds of funding as of 2022.

The company engages in the development of microbial sequencing and microbial genome big data analysis. Its main product is the Illumina sequencing platform. The Illumina sequencing platform provides biological information analysis services for genome, transcriptome, and methylation sequencing.

## Funding rounds

- Series C, Jan 21, 2022, $47M — LYFE Capital, Shanghai Biomedical Fund
- Series B, Jul 20, 2021, $31M — Sinovation Ventures, LYFE Capital
- Series A, Sep 28, 2020, $32M — NLVC, Sinovation Ventures, CD Capital, Lapam Capital
- Angel, Feb 25, 2020 — NLVC

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Angel, Series A
- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series A, Series B
- CD Capital — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- LYFE Capital — Series B, Series C
- Shanghai Biomedical Fund — Series C